Safety, tolerability, pharmacokinetic profile and ex-vivo antitubercular acativity of macozinone formulated as spraydredi dispersion (SDD) versus native crystal powder (NCO?: single ascending doses, randomized, placebo-controlled, cross-ouver phase la trial in healthy volunteers

Details

Request a copyRequest a copy
Serval ID
serval:BIB_B502CD64B984
Type
Inproceedings: an article in a conference proceedings.
Collection
Publications
Institution
UNIL/CHUV
Title
Safety, tolerability, pharmacokinetic profile and ex-vivo antitubercular acativity of macozinone formulated as spraydredi dispersion (SDD) versus native crystal powder (NCO?: single ascending doses, randomized, placebo-controlled, cross-ouver phase la trial in healthy volunteers
Title of the conference
SGAIM/SSMIG 6th Spring Congress Lausanne, June 2022. Primary and Hospital Care 2022: 22 (Suppl. 12), 173
Author(s)
Rothuizen L.E., Ciullini L., Huser-Pitteloud J., Guidi M., Chtioui H., Ivanyuk A., André P., Bardinet C., Decosterd L.A., Spaggiari D., Brunner-Ferber F., Gillon J.Y., Blattes E., Vocat A., Cole S., Buclin T.
Publication state
Published
Issued date
2022
Language
english
OAI-PMH
oai:serval.unil.ch:BIB_B502CD64B984
Create date
13/01/2023 16:04
Last modification date
18/03/2023 6:45
Usage data